

MEDICINES MANAGEMENT OPERATIONAL GROUP UPDATE REPORT

Meetings held: 12 March 2024, 21 May 2024, 16 July 2024, 17 Sept 2024.

Report by: Dr Subhamay Ghosh (Associate Medical Director For Quality & Safety),
Chair

KEY DISCUSSION POINTS AND MATTERS TO BE ESCALATED FROM THE DISCUSSION AT THE MEETING:

Alert¹ (may require discussion)

The Medicines Management Operational Group wish to **alert** members of the Quality Safety and Experience Committee that:

- Completion of Venous Thromboembolic Risk Assessments continues to be poor even though the prescribing of prophylaxis has improved. [Thrombosis Sub-group March 2024]. Request: Support to encourage the completion of assessments is requested.
- Buvidal funding from Welsh Government finishes 2025. [Local Intelligence Network; May 2024] Patients moved to Buvidal during Pandemic and in response to reduced provision of Supervised Consumption by Community Pharmacies. Funding is being sought via the Area Planning Board.

Advise² (to monitor)

The Medicines Management Operational Group wish to **advise** members of the Quality Safety and Experience Committee that:

- Valproate/topiramate review of prescribing following the Medicines and Healthcare products Regulatory Agency (MHRA) alerts. [Medicines Event Review Group] Support to ensure that all patients (aged 13 to 55 years old) have been reviewed and the appropriate risk assessment forms are completed including HDUHB patients managed by commissioned services.
- Continued progress on National Prescribing Indicators relating to gabapentanoids and strong opioids (RR 1404). The Health Board, while making progress, remains one of the highest prescribing Health Boards in Wales.

Assure³ (to note)

The Medicines Management Operational Group wish to assure members of the Quality Safety and Experience Committee that:

The Health Board has made the best progress on the decarbonisation of inhalers in Wales.

¹ There is a lack of confidence that any action in place is sufficient to address the issue satisfactorily and/or within the scope of the operational team or executive to resolve. Engagement, action or intervention required.

² There are areas of concern where assurance has been taken on actions in place but requires close monitoring. An early warning of an emerging and potentially serious concern.

³ There is confidence that actions are robust and will be sufficient to address the issue or generally operating effectively. Routine monitoring.

Performance against the National Prescribing Indicators for antimicrobials continues steady improvement.

The transfer of the Accountable Officer for Controlled Drugs from Dr Phil Kloer to Mr Mark Henwood was completed in May 2024.

Review of Risks

- RR681 Drug Error Reduction Library update has been completed and approved. Roll-out and training is being undertaken by Clinical Engineering, medical device trainers and nursing over the 6 months.
- RR1810 Aseptic Services There is a delay in submitting the business case to Welsh Government due to a lack of response in the initial tendering process. Planning is taking further action to progress.
- electronic Prescribing and Medicines Administration system (ePMA) has been approved in principle by Welsh Government. The Health Board is waiting on confirmation of funding prior to starting the next phase of implementation.

All risks which are aligned to Medicines Management have been reviewed and the meetings have considered the status of each risk and the current score of each risk. Six risks have been closed in 2024.

Sharing of learning

Thirty three written control documents have been approved or advised on by MMOG March-September 2024 and shared across the Health Board.

Recommendation

The Sub Committee is asked to note this report.